Hong Kong Equities Flash Mixed Signals as Airlines Brace for Losses, Biotech Advances

A slew of Hong Kong-listed companies spanning aviation, biotechnology, and heavy machinery are charting diverging paths in mid-2026, underscored by sharp profit warnings, aggressive share buybacks, and steady clinical advancements, according to recent corporate filings and market data.

China Eastern Airlines

中国东方航空股份 (0670.HK) is bracing for significant headwinds. The company issued a profit warning for the first half of 2026, forecasting net losses up to RMB 2.4 billion. The widening loss is largely driven by a spike in aviation fuel prices, according to the airline, reversing the RMB 1.63 billion profit recorded in the first quarter. To buffer market sentiment, the carrier recently repurchased A-shares worth RMB 30 million.

COSCO Shipping Development

中远海发 (2866.HK) is accelerating its asset expansion, announcing the purchase of 24 dry bulk vessels in late June to bolster its industry synergy. For Q1 2026, the company posted a 10.49% increase in revenue to RMB 5.98 billion, although net income attributable to shareholders slipped 14.01%, reflecting shifting margins in its container operations.

First Tractor

Buoyed by robust export data for heavy machinery, 第一拖拉机股份 (0038.HK) is moving to stabilize its valuation. The company is seeking shareholder approval to buy back up to 10% of its issued H-shares. Meanwhile, FIL Limited increased its stake in the firm to 7.00% following a recent market purchase valued at roughly HKD 1.39 million.

SinoHytec

The hydrogen fuel cell sector remains mired in early-stage commercialization hurdles. 亿华通 (2402.HK) disclosed that its subsidiary is suing a partner for RMB 162 million in unpaid contracts. Despite revenue surging 58.40% in Q1 2026, the firm remains unprofitable amid slow cash collection and intense price competition.

Junshi Biosciences

On the biotech front, 君实生物 (1877.HK) is steadily advancing its pipeline. The company's supplemental new drug application for its anti-PD-1 monoclonal antibody in resectable non-small cell lung cancer was accepted in July. The firm also inked a commercialization partnership for an IL-17A antibody earlier this month.

Livzon Pharmaceutical

Navigating a management transition in 2026, 丽珠医药 (1513.HK) recently completed the first patient dosing in a Phase I clinical trial for its new injection microspheres. However, its core operations face pressure from raw material price volatility, prompting the new leadership to seek fresh growth catalysts.

Cutia Therapeutics

科笛-B (2487.HK) secured a major regulatory milestone with the approval of its topical anesthetic cream for dermatological surgeries. This marks a critical step in commercializing its epidermal anesthesia portfolio.

Jufutang Bio

Small-cap biotech 菊福堂生物 (8217.HK) posted a turnaround, reporting a net profit of HKD 23.3 million for the fiscal year ended March 2026. The profitability was largely driven by HKD 27 million in fair value gains on financial assets.

Market Laggards

In the broader market, traditional drugmakers like 山东新华制药股份 (0719.HK) and niche quantitative plays like XI 二南策略-U (9399.HK) are navigating a tepid liquidity environment. Market watchers indicate that the valuation gap between cash-generating industrials and speculative tech assets is poised to widen as Q3 unfolds.

This article does not constitute investment advice.